Your browser doesn't support javascript.
loading
Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data.
Al Khleifat, Ahmad; Iacoangeli, Alfredo; Jones, Ashley R; van Vugt, Joke J F A; Moisse, Matthieu; Shatunov, Aleksey; Zwamborn, Ramona A J; van der Spek, Rick A A; Cooper-Knock, Johnathan; Topp, Simon; van Rheenen, Wouter; Kenna, Brendan; Van Eijk, Kristel R; Kenna, Kevin; Byrne, Ross; López, Victoria; Opie-Martin, Sarah; Vural, Atay; Campos, Yolanda; Weber, Markus; Smith, Bradley; Fogh, Isabella; Silani, Vincenzo; Morrison, Karen E; Dobson, Richard; van Es, Michael A; McLaughlin, Russell L; Vourc'h, Patrick; Chio, Adriano; Corcia, Philippe; de Carvalho, Mamede; Gotkine, Marc; Panades, Monica Povedano; Mora, Jesus S; Shaw, Pamela J; Landers, John E; Glass, Jonathan D; Shaw, Christopher E; Basak, Nazli; Hardiman, Orla; Robberecht, Wim; Van Damme, Philip; van den Berg, Leonard H; Veldink, Jan H; Al-Chalabi, Ammar.
Afiliación
  • Al Khleifat A; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • Iacoangeli A; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • Jones AR; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • van Vugt JJFA; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • Moisse M; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • Shatunov A; Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Leuven, Belgium.
  • Zwamborn RAJ; VIB Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.
  • van der Spek RAA; Institute of Medicine, North-Eastern Federal University, Yakutsk, Russia.
  • Cooper-Knock J; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
  • Topp S; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • van Rheenen W; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • Kenna B; Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom.
  • Van Eijk KR; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • Kenna K; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • Byrne R; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • López V; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • Opie-Martin S; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • Vural A; Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
  • Campos Y; Computational Biology Unit, Instituto de Salud Carlos III, Madrid, Spain.
  • Weber M; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • Smith B; School of Medicine, Translational Medicine Research Center-NDAL, Koc University, Istanbul, Turkey.
  • Fogh I; Computational Biology Unit, Instituto de Salud Carlos III, Madrid, Spain.
  • Silani V; School of Medicine, Translational Medicine Research Center-NDAL, Koc University, Istanbul, Turkey.
  • Morrison KE; Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Dobson R; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • van Es MA; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, United Kingdom.
  • McLaughlin RL; Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Vourc'h P; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy.
  • Chio A; Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, Belfast, United Kingdom.
  • Corcia P; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • de Carvalho M; Institute of Health Informatics, University College London, London, United Kingdom.
  • Gotkine M; Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands.
  • Panades MP; Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
  • Mora JS; Centre SLA, CHRU de Tours, Tours, France.
  • Shaw PJ; Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.
  • Landers JE; Azienda Ospedaliera Citta della Salute e della Scienza, Turin, Italy.
  • Glass JD; Centre SLA, CHRU de Tours, Tours, France.
  • Shaw CE; Federation des Centres SLA Tours and Limoges, LITORALS, Tours, France.
  • Basak N; Physiology Institute, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal.
  • Hardiman O; Department of Neurology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Robberecht W; Department of Neurology, Hospital Universitari de Bellvitge, Barcelona, Spain.
  • Van Damme P; Hospital San Rafael, Madrid, Spain.
  • van den Berg LH; Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom.
  • Veldink JH; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, United States.
  • Al-Chalabi A; Department of Neurology, Center for Neurodegenerative Diseases, Emory University, Atlanta, GA, United States.
Front Cell Neurosci ; 16: 1050596, 2022.
Article en En | MEDLINE | ID: mdl-36589292
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to progressive weakness of voluntary muscles, with death following from neuromuscular respiratory failure, typically within 3 to 5 years. There is a strong genetic contribution to ALS risk. In 10% or more, a family history of ALS or frontotemporal dementia is obtained, and the Mendelian genes responsible for ALS in such families have now been identified in about 50% of cases. Only about 14% of apparently sporadic ALS is explained by known genetic variation, suggesting that other forms of genetic variation are important. Telomeres maintain DNA integrity during cellular replication, differ between sexes, and shorten naturally with age. Sex and age are risk factors for ALS and we therefore investigated telomere length in ALS. Methods: Samples were from Project MinE, an international ALS whole genome sequencing consortium that includes phenotype data. For validation we used donated brain samples from motor cortex from people with ALS and controls. Ancestry and relatedness were evaluated by principal components analysis and relationship matrices of DNA microarray data. Whole genome sequence data were from Illumina HiSeq platforms and aligned using the Isaac pipeline. TelSeq was used to quantify telomere length using whole genome sequence data. We tested the association of telomere length with ALS and ALS survival using Cox regression. Results: There were 6,580 whole genome sequences, reducing to 6,195 samples (4,315 from people with ALS and 1,880 controls) after quality control, and 159 brain samples (106 ALS, 53 controls). Accounting for age and sex, there was a 20% (95% CI 14%, 25%) increase of telomere length in people with ALS compared to controls (p = 1.1 × 10-12), validated in the brain samples (p = 0.03). Those with shorter telomeres had a 10% increase in median survival (p = 5.0×10-7). Although there was no difference in telomere length between sporadic ALS and familial ALS (p=0.64), telomere length in 334 people with ALS due to expanded C9orf72 repeats was shorter than in those without expanded C9orf72 repeats (p = 5.0×10-4). Discussion: Although telomeres shorten with age, longer telomeres are a risk factor for ALS and worsen prognosis. Longer telomeres are associated with ALS.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Cell Neurosci Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Cell Neurosci Año: 2022 Tipo del documento: Article